Analyst consensus rating
Telomir Pharmaceuticals Analyst Rating: none
Direct answer
Telomir Pharmaceuticals's consensus rating is none.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $4.00.
Forecast evidence checked November 5, 2026.
Get free Telomir Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.78
- Average price target
- $4.00
- High price target
- $4.00
- Low price target
- $4.00
- Low target gap
- +412.8%
- Target upside
- +412.8%
- High target gap
- +412.8%
- Target range width
- 0%
- Consensus rating
- none
- Analysts
- 1
- Evidence date
- November 5, 2026
- Valid through
- November 12, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Telomir Pharmaceuticals?
Telomir Pharmaceuticals has a verified none consensus. The same dataset has an average price target of $4.00.
How far are Telomir Pharmaceuticals's low and high targets from the recorded price?
The low target implies +412.8%, while the high target implies +412.8%.
How many analysts are included in Telomir Pharmaceuticals's consensus?
The verified consensus includes 1 analysts.
How is Telomir Pharmaceuticals's target upside or downside calculated?
The average target of $4.00 is divided by the recorded price of $0.78, then one is subtracted to produce +412.8%. This does not guarantee a future return.
When was Telomir Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-11-05. The dataset is valid through 2026-11-12.